Zydus Lifesciences reported that its injectable manufacturing plant near Vadodara, Gujarat, received ten observations from the US Food and Drug Administration (USFDA) after an inspection from April 15 to April 23. The company stated its commitment to working closely with the USFDA to address the observations promptly. As a result, shares of the company were trading 2.79% lower at Rs 932.80 apiece on the BSE.